文献速递肿瘤 PET/CT核素与放射性配体治疗

PSMA靶向药物[18F]AlF-P16-093的首次人体研究:前列腺癌患者的剂量学与初步评估

First-in-human study of PSMA-targeting agent, [18F]AlF-P16-093: dosimetry and initial evaluation in prostate cancer patients.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-01-12

这项首次人体研究评估了新型PSMA靶向放射性药物[18F]AlF-P16-093的辐射剂量学及其在前列腺癌患者中检测PSMA阳性肿瘤的初步能力。23例经组织病理学证实的前列腺癌患者被前瞻性纳入,其中6例进行剂量学与生物分布研究。结果显示该药物合成成功,放射化学纯度>95%,平均标记产率36.5±8.3%(衰变校正,n=12),有效剂量为16.8±1.3 μSv/MBq,较[68Ga]Ga-P16-093低约30%;所有受试者耐受良好,无报告的不良反应,PSMA阳性肿瘤在10分钟内均可检出。

要点

  • [18F]AlF-P16-093放射化学纯度>95%,平均标记产率36.5±8.3%(衰变校正,n=12)。
  • 有效剂量为16.8±1.3 μSv/MBq,较[68Ga]Ga-P16-093低约30%。
  • 所有PSMA阳性肿瘤在10分钟内快速摄取并可检出,后续多时间点扫描未见额外病灶。

核心结论

  • 报告了一种高产率合成[18F]AlF-P16-093的简化方法。
  • 在前列腺癌患者中的初步研究显示其安全性和可接受的辐射剂量学。
  • 初步诊断研究表明[18F]AlF-P16-093 PET/CT在前列腺癌患者诊断中有效且可能有助于广泛应用。

研究设计与样本

  • 首次人体研究,前瞻性纳入23例经组织病理学证实的前列腺癌患者。
  • 剂量学与生物分布研究在6例前列腺癌患者亚组中进行,涉及多时间点扫描。
  • 使用PMOD和OLINDA软件估算平均吸收剂量。

主要发现

  • [18F]AlF-P16-093成功合成,放射化学纯度>95%,平均标记产率36.5±8.3%(衰变校正,n=12)。
  • 肾脏、脾脏和肝脏摄取最高,有效剂量为16.8±1.3 μSv/MBq,较[68Ga]Ga-P16-093低约30%。
  • 所有受试者耐受PET检查良好,未观察到可报告的不良反应。
  • PSMA阳性肿瘤显示快速摄取,均在10分钟内可检出,后续多时间点扫描未观察到额外病灶。
  • 每例患者至少有一个可检测的肿瘤病灶,共观察到356个肿瘤病灶,包括前列腺内、淋巴结转移、骨转移和其他软组织转移。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This is a first-in-human study to evaluate the radiation dosimetry of a new prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical, [18F]AlF-P16-093, and also initial investigation of its ability to detect PSMA-positive tumors using PET scans in a cohort of prostate cancer (PCa) patients. METHODS: The [18F]AlF-P16-093 was automatically synthesized with a GE TRACERlab. A total of 23 patients with histopathologically proven PCa were prospectively enrolled. Dosimetry and biodistribution study investigations were carried out on a subset of six (6) PCa patients, involving multiple time-point scanning. The mean absorbed doses were estimated with PMOD and OLINDA software. RESULTS: [18F]AlF-P16-093 was successfully synthesized, and radiochemical purity was > 95%, and average labeling yield was 36.5 ± 8.3% (decay correction, n = 12). The highest tracer uptake was observed in the kidneys, spleen, and liver, contributing to an effective dose of 16.8 ± 1.3 μSv/MBq, which was ~ 30% lower than that of [68Ga]Ga-P16-093. All subjects tolerated the PET examination well, and no reportable side-effects were observed. The PSMA-positive tumors displayed rapid uptake, and they were all detectable within 10 min, and no additional lesions were observed in the following multi-time points scanning. Each patient had at least one detectable tumor lesion, and a total of 356 tumor lesions were observed, including intraprostatic, lymph node metastases, bone metastases, and other soft tissue metastases. CONCLUSIONS: We report herein a streamlined method for high yield synthesis of [18F]AlF-P16-093. Preliminary study in PCa patients has demonstrated its safety and acceptable radiation dosimetry. The initial diagnostic study indicated that [18F]AlF-P16-093 PET/CT is efficacious and potentially useful for a widespread application in the diagnosis of PCa patients.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Zhao R, Ke M, Lv J, et al. First-in-human study of PSMA-targeting agent, [18F]AlF-P16-093: dosimetry and initial evaluation in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2024. PMID: 38212531. doi:10.1007/s00259-024-06596-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。